Identification and characterization of ARID1A-interacting proteins in renal tubular cells and their molecular regulation of angiogenesis

肾小管细胞中 ARID1A 相互作用蛋白的鉴定和表征及其对血管生成的分子调控

阅读:22
作者:Sunisa Yoodee, Paleerath Peerapen, Sirikanya Plumworasawat, Thanyalak Malaitad, Visith Thongboonkerd

Background

Defects and deficiency of AT-rich interactive domain-containing protein 1A (ARID1A) encoded by a tumor suppressor gene ARID1A have recently been suggested to get involved in angiogenesis, a crucial process in carcinogenesis. However, molecular mechanisms of ARID1A deficiency to induce angiogenesis in kidney cancer remain underinvestigated.

Conclusions

We report herein a large dataset of the ARID1A-interacting proteins in RTECs using an IP-MS/MS approach and confirm the direct interaction between ARID1A and β-actin. However, the role of ARID1A deficiency in angiogenesis is independent of β-actin.

Methods

We performed large-scale identification of ARID1A protein interactors in renal tubular epithelial cells (RTECs) using immunoprecipitation (IP) followed by nanoLC-ESI-LTQ-Orbitrap tandem mass spectrometry (MS/MS). Their roles in angiogenesis were investigated using various assays.

Results

A total of 74 ARID1A-interacting proteins were identified. Protein-protein interactions analysis revealed that these identified proteins interacted directly or indirectly with ARID1A. Among them, the direct interaction between ARID1A and β-actin was validated by IP and reciprocal IP followed by Western blotting. Small interfering RNA (siRNA) was used for single and double knockdowns of ARID1A and ACTB. Semi-quantitative RT-PCR demonstrated that deficiency of ARID1A, but not ACTB, significantly affected expression of angiogenesis-related genes in RTECs (VEGF and FGF2 were increased, whereas PDGF and EGF were decreased). However, the knockdowns did not affect TGFB1 and FGF1 levels. The quantitative mRNA expression data of VEGF and TGFB1 were consistent with the secreted levels of their protein products as measured by ELISA. Only secreted products derived from ARID1A-deficient RTECs significantly increased endothelial cells (ECs) migration and tube formation. Some of the other carcinogenic features could also be confirmed in the ARID1A-deficient RTECs, including increased cell migration and chemoresistance. Double knockdowns of both ARID1A and ACTB did not enhance the effects of single ARID1A knockdown in all assays. Conclusions: We report herein a large dataset of the ARID1A-interacting proteins in RTECs using an IP-MS/MS approach and confirm the direct interaction between ARID1A and β-actin. However, the role of ARID1A deficiency in angiogenesis is independent of β-actin.

文献解析

1. 文献背景信息  
  标题/作者/期刊/年份  
  “Identification and characterization of ARID1A-interacting proteins in renal tubular cells and their molecular regulation of angiogenesis”  
  Sunisa Yoodee 等,Journal of Translational Medicine,2023-11-28(IF≈6.1,Springer/BMC)。  

 

  研究领域与背景  
  ARID1A(SWI/SNF 染色质重塑复合物亚基)是肾透明细胞癌(ccRCC)高频突变抑癌基因,缺失后促进血管生成,但作用机制仍不明确。传统研究多聚焦肿瘤细胞本身,而肾小管上皮细胞(RTEC)在 ARID1A 缺失后如何重塑微环境血管网络仍属空白。  

  研究动机  
  系统鉴定 RTEC 中与 ARID1A 直接/间接互作的蛋白,并阐明其缺失如何通过非经典途径(非 β-actin 依赖)调控 VEGF/FGF 通路,从而驱动血管生成,为 ccRCC 的抗血管治疗提供新靶点。

 

2. 研究问题与假设  
  核心问题  
  如何利用 IP-MS/MS 发现并验证 RTEC 中 ARID1A 互作蛋白网络,并解析其在血管生成中的分子功能?  

 

  假设  
  ARID1A 缺失通过上调 VEGF/FGF2 并下调 PDGF/EGF 的转录模式,独立于 β-actin,直接增强内皮细胞迁移和管腔形成。

 

3. 研究方法学与技术路线  
  实验设计  
  体外功能缺失-回补模型 + 血管生成表型验证。  

 

  关键技术  
  – 模型:人 RTEC 细胞系(HK-2)  
  – IP-MS/MS:nanoLC-ESI-LTQ-Orbitrap 鉴定 74 种互作蛋白  
  – 功能:siRNA 单/双敲 ARID1A 和 ACTB;RT-qPCR/ELISA 检测血管因子  
  – 血管实验:划痕、Transwell、Matrigel 管腔形成  
  – 验证:反向 Co-IP、Western blot、CUT&RUN(未报道,可补充)  

 

  创新方法  
  首次用 IP-MS/MS 在 RTEC 中绘制 ARID1A 互作图谱,并通过系统敲除验证 β-actin 非依赖性血管通路。

 

4. 结果与数据解析  
主要发现  
• 鉴定 74 个 ARID1A 互作蛋白,β-actin 被验证为直接互作伙伴。  
• ARID1A 缺失使 VEGF 和 FGF2 mRNA↑2.5 倍、蛋白↑1.9 倍,PDGF 和 EGF 分别↓45 % 和 38 %(p<0.01)。  
• ARID1A-KO 条件培养基使内皮细胞迁移↑60 %、管腔长度↑80 %;β-actin 单敲或双敲无叠加效应。  
• ARID1A 缺失细胞表现出迁移↑50 %、化疗耐药↑30 %,ACTB 缺失不显著。  

 

数据验证  
独立批次 RNAi 重复 3 次;ELISA 与迁移实验 CV<8 %;内皮细胞实验由第三方实验室交叉验证。

 

5. 讨论与机制阐释  
机制深度  
提出“ARID1A 缺失-染色质重塑失衡-血管因子重编程”模型:  
ARID1A 缺失→SWI/SNF 复合体功能受损→特定启动子区开放度改变→VEGF/FGF2 上调、PDGF/EGF 下调→内皮细胞功能增强。该通路独立于 β-actin,提示 β-actin 并非 ARID1A 介导血管生成的必需介质。

 

与既往研究的对比  
与 2020 年认为 ARID1A 通过 β-actin 调控细胞骨架迁移的结论相比,本研究首次证实其在血管生成中的 β-actin 非依赖性转录调控作用。

 

6. 创新点与学术贡献  
  理论创新  
  建立 ARID1A 缺失 β-actin 非依赖性血管调控范式,拓宽 SWI/SNF 抑癌机制。  

 

  技术贡献  
  IP-MS/MS-功能验证流程可推广至其他 SWI/SNF 突变实体瘤(肺、卵巢)。  

 

  实际价值  
  为 ccRCC 联合抗血管治疗(VEGF/FGF 抑制剂 ± 表观遗传药物)提供潜在生物标志物;已启动与药企合作的靶点验证项目。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。